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Abstract This study aimed to investigate symptom
reduction via the liposomal nasal spray LipoNasal (LN) in
patients with rhinitis sicca. Tolerability and the impact on
quality of life were also examined. The same parameters
were established in parallel for treatment approaches with
Bepanthen (BP) nasal ointment containing dexpanthenol
and the Rhinomer (RH) nasal spray containing NaCl. This
prospective, controlled, open-label observation study was a
multicenter trial. 92 patients with rhinitis sicca were allo-
cated to three arms according to their symptoms: LN:
n = 33; BP: n = 32 and RH: n = 27. The study comprised
three visits at an interval of 14 days. Efficacy was examined
by the Rhinitis Sicca Symptom Score (RSSS) documented
daily and at the visits based on an endoscopic evaluation.
The nasal spray sensory scale was used to investigate the
tolerability. Quality of life (QoL) was measured by means
of the Rhinoconjunctivitis Quality of Life Questionnaire
(RQLQ) and the ‘‘Short Form 12’’ of the ‘‘Impact on
Health-Related Quality of Life (HRQL)’’ questionnaire on
general quality of life. Nasal symptoms improved signifi-
cantly (p = 0.001) under all three treatment approaches,
reflected by the reduction in the RSSS and the Endoscopy
Sum Score. A comparison of the three groups showed that
no therapy was significantly superior to any of the others
(p = 0.410). The tolerability of all treatments was good.
Concerning the nasal moisturization, LipoNasal was eval-
uated better than Bepanthen and Rhinomer. Quality of life
improved in all groups, but not significantly. The results
show good efficacy and tolerability of the liposomal nasal
spray compared to generally recognized treatments of
rhinitis sicca with dexpanthenol nasal ointment and NaCl
nasal spray. LipoNasal therefore constitutes a good treat-
ment for patients suffering from dry nose.
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Introduction
The term ‘‘dry nose’’ has not yet been uniformly defined
[1]. Otolaryngologists often use the terms ‘‘rhinitis sicca’’
or ‘‘dry rhinitis,’’ although no clear definition exists;
characteristic for the disorder, however, is hypotrophy of
the nasal mucosa [2].
The symptoms of rhinitis sicca are manifold and range
from the subjective sensation of a dry nose to visible
crusting. Because of the dry nasal mucosa, patients often
suffer from various combinations of rhinitis sicca symp-
toms: sensation of dryness in the nose, itching, mild
burning, impaired nasal breathing, crusting, possibly with
unpleasant odor (ozena), epistaxis, anosmia, and concom-
itant pharyngitis.
The mechanical and functional intactness of the mucus
membranes is an important defense mechanism against
infections. Depending on how much they dry out, muco-
ciliary transport or even the epithelial barrier can be
adversely affected. Such symptoms can markedly impair
the quality of life of affected patients and result in con-
siderable socio-economic burdens, especially in the case of
fetid crusting in so-called ozena as the severest form of
rhinitis sicca. These patients therefore visit ears–nose–
throat (ENT) offices often and repeatedly.
Used for treatment of rhinitis sicca anterior and after
nasal and sinus surgery, dexpanthenol has been available as
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a nasal ointment without preservatives (Bepanthen Roche
Eye and Nose Ointment) since the 1960s [3]. Dexpanthenol
is an active ingredient that promotes wound healing. It is
converted in vivo to pantothenic acid, a component of
coenzyme A which in turn activates fibroblast proliferation
and accelerates the reepithelialization process [4]. In a
study by Kehrl and Sonnemann [5], the effect of dexpan-
thenol in rhinitis sicca has been scientifically verified.
Other local treatment approaches consist of nasal rinses,
moisturizing nasal sprays (NaCl), inhalations, and oils.
Nasal rinses are listed in the guidelines for treating rhi-
nosinusitis, although they are not explicitly recommended
for use in rhinitis sicca [6]. The positive effect of nasal
rinses and nasal sprays containing NaCl is based on
moistening the nasal mucosa and softening of any existing
crusts.
An alternative to local therapy of dry nose is the
application of LipoNasal nasal spray, which contains
liposomes composed of phospholipids, fatty acids, and
vitamin E. This therapy approach involves the supple-
mentation of phospholipids as the most important compo-
nent of the body’s own surfactant. It is meant to restore the
protective secretion film, whose functions are moistening,
mucosal defense, and mucociliary transport [7, 8].
The study described here investigated the properties of
this liposomal nasal spray in the treatment of patients
suffering from rhinitis sicca in routine clinical practice.
Data on the efficacy, tolerability, and quality of life were
gathered to this purpose. The investigation was designed as
a prospective, nonrandomized observation study with an
active control. The comparative groups were treated with a
dexpanthenol nasal ointment and a nasal spray containing
NaCl. The present study was conducted in compliance with
good clinical practice guidelines. Since the nasal sprays
and ointment are available without a prescription, approval
by an ethics committee was not required. Prior to the study,
however, a professional legal consultation took place with
the appropriate ethics committee.
Methods
Study design
This trial was a prospective, controlled, open-label
observation study. From 12 May 2011 to 12 December
2011, a total of 92 patients were enrolled at seven ENT
trial sites. All patients were 12 years or older and suffered
from rhinitis sicca. Patients visited the trial site because
of symptoms resulting from this condition. Restricted
inclusion of patients in the post-marketing surveillance
study based on the indication of rhinitis sicca and strict
adherence to the principle of non-intervention allowed
data to be collected for the most unselective patient
population as possible. The investigators, taking the
patient into consideration, were free to decide who was to
receive which medication. The study consisted of a total
of 28 ± 2 observation days, where Visit 1 took place on
the first day (V1), Visit 2 after 14 ± 2 days (V2), and
Visit 3 after 28 ± 2 days (V3).
Medication
LipoNasal Nasenpflege Spray (LN) is produced by
Optima Pharmazeutische GmbH, Moosburg. Other ingre-
dients of the nasal spray than the liposomes are soja leci-
thin, sodium chloride, ethanol, dexpanthenol, vitamin A
palmitate, vitamin E, and aqua purificata. Treatment was
conducted according to the information in the package
leaflet. On average, 3–3 sprays of LN per nostril per day
were used; in the course of a day, a total of 0.5–0.6 ml of
the liposomal suspension was applied to the nasal mucosa.
Bepanthen Eye and Nose Ointment (BP), manufac-
tured by Bayer Vital GmbH, Leverkusen, is a product that
promotes wound healing. Dexpanthenol is the active
ingredient (1 g ointment contains 0.05 g dexpanthenol).
Other components are: rac-(3R)-3-hydroxy-4.4-dim-
ethyloxolan-2-one; lanolin; viscous paraffin; petroleum
jelly; water for injection. A 1-cm long ribbon of ointment
should be applied to the nasal mucosa and rubbed in gently
once to several times daily. The patients used an average of
2–2 ribbons per nostril per day.
Rhinomer Nasal Spray (RH) is a medicinal product
made by Novartis Consumer Health GmbH, Munich. RH
contains sterile, isotonized seawater spray. When applied
in rhinitis, it serves to moisten the nasal mucosa and sup-
ports the cleansing function of the mucosa’s ciliated epi-
thelium. A dose of 1–2 sprays in each nostril several times
a day as needed is recommended. RH was used between
2 and 3 times daily on average.
Study protocol
Demographic data were recorded during an admission
interview and physical examination on Visit 1 by ENT
specialists.
The documented number of sprays applied per nostril
per day allowed a better understanding of the amount of
nasal spray used and patient compliance.
Efficacy was examined via the Rhinitis Sicca Symptom
Score (RSSS). The severities of the symptoms dryness,
obstruction of nasal breathing, and crusting were rated on
an ordinal scale of 0–3 (0 = no, 1 = mild, 2 = moderate,
3 = severe), and the individual values were added to
obtain a sum score. In addition, the occurrence of frequent
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concomitant symptoms such as itching and pain in the nose,
concomitant pharyngitis, epistaxis, and anosmia were doc-
umented. These symptoms were recorded at each visit by
the investigator, but also daily by the patient himself in a
diary. In order to make an additional objective assessment
of efficacy possible, the investigator performed an endo-
scopic examination of the nasal cavity at Visits 1, 2, and 3
and classified crusting, dryness of the mucosa, redness and
swelling of the inferior and middle nasal turbinates, and
possible ulcerous changes of the nasal mucosa on a 3-point
scale (0 = no, 1 = mild, 2 = severe). The endoscopy score
(ES) was calculated from these data.
After applying the respective nasal spray for the first
time, the patient specified the perceived duration of action
(only for minutes, \1, 1–2, 2–4, [4 h, no effect).
The Nasal Spray Sensory Scale (NSSS) served to
examine tolerability [9] by measuring the patients’ sensory
perception immediately following the first nasal spray
application and 2 min thereafter. Fourteen questions per-
taining to sensory parameters could be answered by
marking a visual analog scale (0 = poor evaluation,
100 = good evaluation). The safety of the treatments was
examined via exact documentation of adverse events.
Since no disease-specific quality of life questionnaire
exists designed especially for patients with rhinitis sicca,
the Rhinoconjunctivitis Quality of Life Questionnaire
(RQLQ) [10] was used which was developed for rhino-
conjunctivitis patients. The SF-12 [11] questionnaire was
also implemented to gather general quality of life data.
Before and after treatment, patients were asked to assess
the impairment intensity of every item on a point scale;
changes in quality of life could thus be evaluated.
Patients also assessed their subjective well-being daily
on a visual analog scale (0 = very poor, 100 = very good).
At the end of the observation period, the investigator
and patients were able to make a final positive or negative
evaluation of efficacy and tolerability of the nasal spray
used.
Statistical methods
Data were evaluated using SPSS 18 statistics software by
SPSS Inc. Patient data were entered in the SPSS database
two times each by two independent people, and a check for
errors was made thereafter. Input errors were corrected.
At first, all data were analyzed descriptively. After
testing for normal distribution using the Kolmogorov–
Smirnov test, differences of non-normally distributed
dependent variables were examined for significance by
means of the Wilcoxon test and independent variables via
the Mann–Whitney U test. The significance level was set at
a = 0.05 %. Missing values were generally treated as
‘‘missing values’’.
Results
Homogeneity of treated groups at baseline
In all, 92 patients were enrolled in the post-marketing
surveillance study, 32 patients of which were included in
the LN treatment group, 32 patients in the BP group, and
27 patients in the RH group.
Treatment group LN consisted of 19 female and 14 male
patients. 20 female and 12 male patients were included in
the BP treatment group, and 14 female and 13 male
patients were enrolled in the RH group.
Patient ages ranged from 19 to 88 years, the average age
being 56 ± 17.3 years. Age distribution was similar in the
three groups and averaged 51 ± 16.1 years in the LN
group, 58 ± 18.5 years in the BP group, and
60 ± 17.3 years in the RH group (Table 1).
Patients in the LN group had suffered for about
3 years on average from rhinitis sicca, patients in the BP
group for an average of almost 9 years, and patients in the
RH group for an average of 6 years.
Efficacy
Like both of the comparative therapies, LN treatment
resulted in significant improvement in the RSSS
(p \ 0.001) and the ES (p = 0.001) from V1 to V3 that
had been assessed by specialists (Table 2). It was a similar
situation for the RSSS documented daily by the patients in
a diary.
Considering the occurrence of frequent concomitant
symptoms the symptom of itching improved to different
degrees in all three treatment groups: LN from 46.9 to
39.3 %, BP from 50.0 to 35.7 %, and RH from 57.7 to
25.0 %, which constitutes the best result.
At the start of treatment, 42.4 % of patients in the LN
group suffered from concomitant pharyngitis. In compari-
son to the treatment groups BP (161 %) and RH (15.4 %),
the number of affected patients is higher. After 4 weeks,
only 21.4 % of patients in the LN group, no one in the BP
group, and 5 % of patients in the RH group said they had
suffered from concomitant pharyngitis.
Impaired olfaction could be improved only minimally in
the LN group (from 66.7 to 53.6 %). In the BP group, it
Table 1 Demographic data
LN BP RH
Number of patients 33 32 27
Sex (male/female) 14/19 12/20 13/14
Mean age (years) 51 ± 16.1 58 ± 18.5 60 ± 17.3
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could be reduced from 62.5 to 28.6 % and in the RH group
from 53.8 to 35.0 %.
Pain in the nose diminished considerably during the
course of treatment in all three groups. In the LN group it
improved from 28.1 at V1 to 10.7 % at V3, in the RN
group from 26.9 to 10.0 % and in the Bepanthen group,
pain disappeared almost completely (from 31.3 to 3.6 %).
The situation was similar for nosebleeds. About one-
third of the patients suffered from them at study inclusion.
In all three groups, this symptom almost completely dis-
appeared after 4 weeks of treatment (in the LN and BP
groups, one patient each was affected by this symptom).
Table 3 shows the number of patients affected at baseline
and after 4 weeks.
Duration of action
The evaluations of the three trial medications produce an
inconsistent picture when compared. 27 % of the patients in
the RH group stated that they had felt no effect of the nasal
spray after applying it. In group BP, only 10 % of the patients
made the same assessment, and only about 5 % of patients in
the LN group indicated the same. 26 % of the patients who
received LN specified a duration of action of ‘‘1–2 h,’’ while it
was approximately 18 % in the BP and RH groups.
In the LN and BP groups, ca. 35 % of all patients indicated
a duration of action of ‘‘2–4 h’’, whereas it was only about
25 % in the RH group. ‘‘over 4 h’’ duration of action was most
often stated by the patients in the BP group at approximately
30 %; about 21 % in the LN group and approximately 15 %
in the RH group indicated the same effect.
One thus recognizes the clearly poorer assessment of
duration of action for the test medication Rhinomer in com-
parison to the other two products. Bepanthen was generally
evaluated as having the longest duration of action (Fig. 1).
Tolerability and safety
When analyzing the Nasal Spray Sensory Scale, differences
were observed among the three types of treatment
(Table 4). BP and RH achieved better results than LN,
especially in terms of smell and taste. In assessing nasal
moisturization, however, LN was evaluated better
(LN 71.75 ± 22.277, BP 60.28 ± 24.454, and RH
67.08 ± 23.202 out of a possible 100 points).
To be able to recognize a possible habituation to the
nasal treatment, the patients were also asked to evaluate
their nasal spray/ointment at Visits 2 and 3. It became
apparent that the patients perceived the odor intensity of
LipoNasal (74.67 ± 19.944) at Visit 3 somewhat more
pleasant than at V1 (68.42 ± 26.690).
Adverse events occurred during the treatment phase in
all three treatment groups (3 in LN, 3 in BP, and 1 in RH).
Under treatment with LN, one patient with pre-existing
bronchial asthma claimed to have suffered dyspnea
10 days after the start of treatment. This feeling occurred
regularly and was moderately strong. After discontinuation
of the trial medication, dyspnea disappeared, which does
not rule out a correlation with the trial medication.
Furthermore, one case of acute rhinitis and one disorder
not further described occurred, both resulting in early
termination of the study.
Table 2 Efficacy of symptom reduction (Wilcoxon Test)
LN BP RH
Symptom score p values Symptom score p values Symptom score p values
RSSS Visit 1 5.39 ± 1.999 \0.001 5.81 ± 2.151 \0.001 4.62 ± 2.099 \0.001
RSSS Visit 2 3.60 ± 1.754 3.00 ± 1.944 3.39 ± 2.190
RSSS Visit 3 2.83 ± 2.037 2.64 ± 2.129 2.10 ± 0.995
ES Visit 1 4.45 ± 1.697 \0.001 4.48 ± 1.671 \0.001 3.98 ± 1.385 \0.001
ES Visit 2 2.77 ± 1.455 2.57 ± 1.476 2.87 ± 1.842
ES Visit 3 2.55 ± 1.682 2.11 ± 1.672 2.33 ± 1.528
Table 3 Occurance of concomitant symptoms
Patients affected LN BP RH
n = baseline n = 4 weeks n = baseline n = 4 weeks n = baseline n = 4 weeks
Concomitant pharyngitis 14 6 5 0 4 1
Pain 9 3 10 1 7 2
Nosebleeds 10 1 8 1 8 0
Impaired olfaction 22 15 20 8 14 7
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Adverse events in the BP group were mild pharyngitis,
olfactory problems under lasting treatment with BP nasal
ointment, increased encrusting, and headache occurring in
one female patient. A correlation to the trial medication
cannot be ruled out.
In the RH group, increasing impairment of nasal
breathing and moderate headaches occurred occasionally/
periodically in one patient. Symptoms resolved after
adapting concomitant therapy; here, too, a connection to
the trial medication cannot be ruled out.
Quality of life
The RQLQ global score for quality of life declined under
LN therapy from a rating of ‘‘somewhat restricted’’ at V1
to ‘‘few restrictions’’ at V3. Fewer health restrictions were
also stated in the BP and RH group. In the RH group the
baseline value was somewhat lower than the values for LN
and BP (Fig. 2).
The results show that significant improvement in the
RQLQ global score could be achieved with all three trial
medications between V1 and V3 (p B 0.05).
In the category ‘‘impairment of sleep,’’ only LN was
able to achieve significant improvement from V1 to V3
(p = 0.003). When observing the number of valid values at
V1 and V3, respectively; however, it appears that the sta-
tistical significance is only achieved due to study dropouts.
The Kruskall–Wallis test was able to show that no sig-
nificant difference existed in the improvement of the sum
score among the three groups (p [ 0.05).
The analysis of the SF-12 questionnaire also showed a
tendency toward improvement in the sum scales for
physical and mental health. The higher the values, the
better the patients assessed their quality of life. For phys-
ical health, values in the LN group rose from
45.05 ± 11.736 to 48.64 ± 8.518 and in the BP group
from 45.84 ± 7.937 to 48.12 ± 7.498. In the RH group,
the baseline value was somewhat higher at 49.37 ± 7.596,
but did not improve by V3.
In terms of mental health, however, the values of the RH
group improved more strongly from 48.93 ± 9.620 to
53.16 ± 8.198. In the LN group, the values rose from
48.65 ± 9.260 to only 49.00 ± 10.898, and in the BP
group from 47.99 ± 9.470 to 49.80 ± 10.182.
The Wilcoxon test, however, showed that these
improvements in physical and mental health from V1 to V3
were not significant in any group (p [ 0.05). The Kruskall–
Wallis test showed that here, too, there is no significant
difference among the three groups (p [ 0.05).
As for the patient’s subjective state of health, all groups
had baseline values between 50 and 60 documented in their
patient diaries, with the values reaching about 70 points
near the end of treatment. The higher the values, the better
Fig. 1 Comparison of the duration of action within the three groups
Table 4 Four of the 14 items of the nasal spray sensory scale
LN BP RH
Odor intensity Visit 1 68.42 ± 26.690 82.06 ± 16.240 87.00 ± 21.195
Odor intensity Visit 2 79.10 ± 22.768 80.07 ± 18.360 82.65 ± 22.793
Odor intensity Visit 3 74.67 ± 19.944 85.67 ± 12.551 84.45 ± 21.387
Intensity of taste Visit 1 76.45 ± 24.258 88.61 ± 16.814 87.81 ± 19.468
Intensity of taste Visit 2 63.69 ± 27.909 85.36 ± 20.447 84.70 ± 18.605
Intensity of taste Visit 3 72.07 ± 19.036 85.07 ± 22.072 87.68 ± 13.375
Nasal moisturization Visit 1 71.75 ± 22.277 60.28 ± 24.454 67.08 ± 23.202
Nasal moisturization Visit 2 66.28 ± 24.721 62.36 ± 24.497 67.73 ± 21.472
Nasal moisturization Visit 3 70.59 ± 19.753 68.07 ± 21.958 74.90 ± 19.620
Overall impression Visit 1 59.25 ± 28.098 71.47 ± 22.446 74.37 ± 19.960
Overall impression Visit 2 68.31 ± 21.032 69.39 ± 25.300 81.00 ± 15.814
Overall impression Visit 3 65.15 ± 18.749 80.46 ± 17.648 76.30 ± 21.379
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the patient assessed his or her subjective state of health.
This may indicate that all three treatment forms had a
positive effect on the patients’ subjective state of health.
Final assessment
The efficacy of the three trial medications was assessed
somewhat differently by the investigators and the patients.
About two-thirds of the investigators described the efficacy
of all three medications as ‘‘good’’ or ‘‘very good.’’
It appears that in contrast to the investigators, patients
tended to evaluated efficacy more poorly. In the LN group,
half of the patients rated efficacy more negatively; in the
BP group, it was somewhat less at 40 % of patients and in
the RH group over 60 % assessed efficacy more negatively.
Nevertheless, 73.9 % of the patients would recommend LN
nasal spray, 75 % BP, and over 80 % RH.
Generally, it can be said that patients rated the efficacy
of BP the best, followed by LN and RH, which received the
poorest ratings.
Discussion
The aim of this observational study was to gain insight into
the tolerability and the effects on the quality of life of a
liposomal nasal spray, a nasal ointment containing dexpan-
thenol, or an isotonic NaCl spray in patients with rhinitis
sicca under practical conditions. Also to be investigated was
the extent to which the treatment influenced the condition of
the nasal mucosa upon endoscopic evaluation and the
severity of the patients’ symptoms.
A total of 92 patients with a wide variety of disease
severities participated in this post-marketing surveillance
study.
Efficacy
Four-week treatment of the three patient groups led to a
significant reduction in the RSSS (LN 48 %, BP and RH
55 %) and to an improvement in the ES (LN 43 %, BP
53 %, and RH 41 %) for all three investigational products
compared to the assessment prior to treatment start
(p \ 0.001). As early as after 2 weeks of treatment,
symptoms decreased significantly. When comparing the
three test products, no superiority or inferiority could be
ascertained.
The improvements achieved in RSSS and ES show a
therapy effect for the liposomal nasal spray as well as an
effect for both comparative treatments with dexpanthenol
nasal ointment and isotonic NaCl spray, respectively.
In the study by Kehrl and Sonnemann [5] on the treat-
ment of rhinitis sicca anterior with dexpanthenol nasal spray
(active group n = 24) or isotonic saline solution (placebo
group n = 24), nasal airway obstruction and the extent of
crust formation were also assessed to evaluate efficacy (our
study also rated dryness of the nose). The results for the
dexpanthenol product were comparable to our results: sig-
nificant improvements in nasal airway obstruction after 2
and 4 weeks of treatment. In the group using the isotonic
NaCl spray, however, no significant improvements were
achieved, which was just the opposite case in our study.
Verse et al. [12] compared dexpanthenol nasal ointment
with dexpanthenol nasal spray based on mucociliary
clearing time. This test was not performed by any inves-
tigator in our study due to time constraints under practical
conditions; therefore, it is not possible to draw a compar-
ison here.
Mu¨ller-Sacks [13] was able to achieve similarly good
results in his study with nasal sprays containing NaCl. A
post-marketing surveillance study using NaCl nasal spray
was conducted with 205 airline employees who suffered
from rhinitis sicca symptoms at least occasionally. In
88.8 % of the participants, a very good or good moistur-
ization of the nasal mucosa was attained through applica-
tion of the spray, and in more than half of the patients
crusting decreased. Overall, 89 % of participants confirmed
symptom improvement, which in 63.7 % of cases also
meant an increase in quality of life.
In earlier studies with the liposomal nasal spray in
patients with seasonal allergic rhinitis, a significant
reduction in nasal (p = 0.003) and conjunctivitis
(p = 0.005) symptoms could be achieved and quality of
Fig. 2 Development of RQLQ global score
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life improved (LN: p = 0.002) [14–16]. Attention was
thereby drawn to the possible therapeutic potential in
patients with rhinitis sicca.
The liposomal nasal spray investigated here for the first
time for application in rhinitis sicca thus lessens the
symptoms of dry nose to approximately the same extent
than the comparative products already proven in several
studies to be effective.
Duration of action
In the present post-marketing surveillance study, the duration
of action of the liposomal nasal spray was evaluated better
than that of the isotonic NaCl spray, although the dexpan-
thenol nasal ointment was rated best of all three medicinal
products. No information can be found in the literature with
regard to the duration of action of the individual products.
Tolerability and safety
The tolerability of all three preparations can be evaluated as
good. The analysis of the NSSS at V1 showed only slight
differences in the assessment of the three treatment
approaches. Worth noting is that LN performed better on
average in moisturizing the nose than the other two prepa-
rations (LN 71.75 ± 22.277, BP 60.28 ± 24.454, RH
67.08 ± 23.202). The high standard deviation values make
clear how differently the patients rated their treatments. For
the rest of the parameters, LN nasal spray performed slightly
worse than BP and RH, especially for the parameters smell
and taste. Similar results have already been observed in other
studies on LN [15]. Based on these observations, a new
formula for optimizing smell and test has been used. The
new LN was rated considerably better than the old formula,
but it does not quite achieve the same values as the com-
parative preparations in the assessment of tolerability.
The only adverse event for LN described in detail was
dyspnea in one asthma patient. Such an effect has not been
observed in any of the previously conducted studies with
LN [14–16] and was caused in all likelihood by the
hyperreactive bronchial system, typical in asthma patients
and irrespective of application of the specific product.
In two patients from the BP group and one patient from
the RH group, exacerbation of existing symptoms, such as
olfactory disorders, crusting, and nasal obstruction, has
been described. The question remains open here, too, as to
how these symptoms could have been aggravated. Possible
intolerances cannot be ruled out.
Quality of life
Significant improvement in the RQLQ global score
between V1 and V3 could be achieved with all three test
medications (p B 0.05). No significant difference, how-
ever, existed among the three groups (p [ 0.05).
In the category ‘‘sleep problems,’’ only LN could
achieve significant improvement from V1 to V3
(p = 0.003). Therefore, it is clear that relatively insignifi-
cantly appearing diseases also have an effect on quality of
life. It is questionable whether it is also clinically relevant.
In recording health-related quality of life via the SF-12
questionnaire, values tended to be better after 4 weeks of
treatment; however, these values were not statistically
significant.
Final evaluation
The varying final assessments made by the patients with
respect to efficacy are not plausible at first glance, since
significant symptom reductions took place in all three
groups and no one therapy was superior to any other. It
may possibly be explained in light of the better taste of the
nasal ointment and NaCl nasal spray.
Conclusion
Treatment of rhinitis sicca with LipoNasal nasal spray is a
therapy form well accepted by patients and has a positive
safety profile for side effects.
It is in no way inferior to the other two comparative
treatments in terms of efficacy and its positive effect on
quality of life. In particular due to the best assessment with
respect to moisturizing, LipoNasal can be assessed as a
good treatment for patients suffering from dry nose.
Conflict of interest The authors declare that no conflict of interest
exists. The present publication has been prepared under no influence
by the manufacturer in the context of a university research project. It
was financed using an unrestricted research grant provided by the
manufacturer Optima Pharmazeutische GmbH.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Hildenbrand T, Weber RK, Brehmer D (2011) Rhinitis sicca, dry
nose and atrophic rhinitis: a review of the literature. Eur Arch
Otorhinolaryngol 268(1):17–26
2. Hilding A (1932) Experimental surgery of the nose and sinuses: i.
changes in the morphology of the epithelium following variations
in ventilation. Arch Otolaryngol Head Neck Surg 16:9–18
3. Klo¨cker N, Verse T, Rudolph P (2003) Die schleimhautprotektive
Wirkung von Dexpanthenol in Nasensprays. Erste Ergebnisse
zytotoxischer und zilientoxischer Versuche in vitro. (The pro-
tective effect of dexpanthenol in nasal sprays. First results of
Eur Arch Otorhinolaryngol (2013) 270:2465–2472 2471
123
cytotoxic and ciliary-toxic studies in vitro). Laryngorhinootologie
82(3):177–182
4. Ebner F, Heller A, Rippke F et al (2002) Topical use of dex-
panthenol in skin disorders. Am J Clin Dermatol 3(6):427–433
5. Kehrl W, Sonnemann U (1998) Dexpanthenol-Nasenspray als
wirksames Therapieprinzip zur Behandlung der Rhinitis sicca
anterior. (Dexpanthenol nasal spray as an effective therapeutic
principle for treatment of rhinitis sicca anterior). Laryngorhi-
nootologie 77(9):506–512
6. Papsin B, McTavish A (2003) Saline nasal irrigation: its role as
an adjunct treatment. Can Fam Physician 49:168–173
7. Glowania A, Mo¨sges R, Bo¨hm M, Knopf A, Klimek L (2011)
Das Surfactant-System—ein neuer Therapieansatz fu¨r die
Schleimhaut der oberen Atemwege. Atemweg und Lungenkran-
kheiten 37(Suppl. 1):1–5
8. Huhn C (2012) Die inhalative Substitution von Phosphatidylch-
olin. Atemwegs- und Lungenkrankheiten 38(8):1–9
9. Mo¨sges R, Pasch N, Sayar A et al (2009) Erhebung der senso-
rischen Wahrnehmung und subjektiven Patienteneinscha¨tzung bei
der Verabreichung von Nasenspray—Die Nasen-Spray-Sensorik-
Skala. Laryngo-Rhino-Otol 88(09):587–591
10. Juniper EF, Guyatt GH (1991) Development and testing of a new
measure of health status for clinical trials in rhinoconjunctivitis.
Clin Exp Allergy 21(1):77–83
11. Jenkinson C, Layte R (1997) Development and testing of the UK SF-
12 (short form health survey). J Health Serv Res Policy 2(1):14–18
12. Verse T, Klo¨cker N, Riedel F et al (2004) Dexpanthenol-Na-
senspray vs. Nasensalbe. HNO 52(7):611–615
13. Mu¨ller-Sacks VE, Bode V (1998) Meersalzhaltiges Nasenspray
bei Rhinitis sicca. Ergebnisse einer Anwendungsbeobachtung.
Deutsche Apotheker Zeitung 138(20):73–76
14. Weston LA, Mo¨sges R (2010) Behandlung der saisonalen aller-
gischen Rhinokonjunktivitis mit einem liposomalen Nasenspray.
Allergologie 33(5):196–204
15. Meyer-Gutknecht H, Mo¨sges R (2008) Wirkung eines neuartigen
liposomalen Nasenspray im auf die Symptome der saisonalen
allergische Rhinitis. HNO kompakt (Suppl. 1): 1–5
16. Bo¨hm M, Avgitidou G, El Hassan E, Mo¨sges R (2012) Liposomes:
a new non-pharmacological therapy concept for seasonal-allergic-
rhinoconjunctivitis. Eur Arch Otorhinolaryngol 269(2):495–502
2472 Eur Arch Otorhinolaryngol (2013) 270:2465–2472
123
